January 4, 2018 / 10:55 PM / Updated 7 minutes ago BRIEF-Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies Reuters Staff 
Jan 4 (Reuters) - Helix Biopharma Corp: 
* HELIX BIOPHARMA CORP. SIGNS BINDING LETTER OF INTENT FOR DEVELOPMENT OF NEW CAR-T TECHNOLOGIES 
* SAYS‍ IMMEDIATE FOCUS WILL INVOLVE PRECLINICAL WORK IN SUPPORT OF A NEW IND APPLICATION OF A CAR-T FOR HEMATOLOGICAL MALIGNANCIES​ 
* SAYS ‍FINALIZATION OF COLLABORATIVE BINDING LOI WITH PROMAB BIOTECHNOLOGIES TO DEVELOP CHIMERIC ANTIGEN RECEPTOR CAR-T FOR HEMATOLOGICAL MALIGNANCES AND SOLID TUMOURS​ 
* SAYS UNDER AGREEMENT,CO RETAINS EXCLUSIVE LICENSE FOR COMMERCIALIZATION OF PRODUCT CANDIDATES DEVELOPED ALONE OR IN COMBINATION WITH DOS47​ Source text for Eikon: Further company coverage: